27 March 2026
Linklaters advises on USD 11.0 bn financing by Novartis of the acquisition of Avidity Biosciences
Advising firms
Deal team
17 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Marco Carbonare Lead | Linklaters | Partner | Corporate/M&A | Frankfurt |
| Kevin Roy Lead | Linklaters | Counsel | Corporate/M&A | Frankfurt |
| Danelle Le Cren Lead | Linklaters | Partner | Banking | New York |
| Jeffrey Cohen | Linklaters | Partner | Capital Markets | New York |
| Andres Loera | Linklaters | Counsel | Banking | New York |
| Omer Harel | Linklaters | Counsel | Tax | London |
| Zila Acosta Grimes | Linklaters | Counsel | Financial Regulation | New York |
| Gert-Jan Hendrix | Linklaters | Counsel | Litigation, Arbitration & Investigations | Brussels |
| Alfredo Hwang | Linklaters | Senior associate | Banking | New York |
| Allan Paul Talde | Linklaters | Senior associate | Tax | New York |
| Justin Faulhaber | Linklaters | Associate | Corporate/M&A | Frankfurt |
| Alexander Gatlin | Linklaters | Associate | Corporate/M&A | Frankfurt |
| Marianna Troia | Linklaters | Associate | Corporate/M&A | Frankfurt |
| Rowina Ullner | Linklaters | Other | Capital Markets | Frankfurt |
| Vivian Meng | Linklaters | Associate | Banking | New York |
| Erika Jensen | Linklaters | Associate | Tax | New York |
| Helena Obenheimer | Linklaters | Other | Capital Markets | Frankfurt |
14 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 11bn (USD 11 billion)
- What the figure measures
- Issue size
- Client
- NovartisIssuer
- Counterparties
- Citigroup (Underwriters)
J.P. Morgan (Underwriters)
BNP Paribas (Underwriters)
Deutsche Bank (Underwriters)
Mizuho (Underwriters)
BofA Securities (Underwriters)
HSBC (Underwriters)
Societe Generale (Underwriters)
UBS Investment Bank (Underwriters)